General description
A cell-permeable, highly selective, ATP/GTP-competitive casein kinase II (CKII) inhibitor (IC50 = 900 nM and 1.6 µM for rat liver and human recombinant CKII, respectively) and DYRK (IC50<1 µM for DYRK1a). Specificity for CKII has been reported following the screening of 33 kinases, including PKA, Akt, PKC, MKK1, ERK2, p38, JNK, Lck, Lyn, and Syk. Also reported to inhibit NS3-associated viral helicase activity in hepatitis C virus (HCV) (IC50 = 20 and 60 µM using DNA and RNA substrates, respectively) and West Nile virus (WNV) (IC50 = 1.7 µM and 900 nM using DNA and RNA substrates, respectively).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
CK2 rat liver, human recombinant
Product competes with ATP.
Reversible: yes
Target IC50: 900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively
Packaging
Packaged under inert gas
Physical form
A 10 mM (5 mg/1.15 ml) solution of Casein Kinase II Inhibitor I (Cat. No. 218697 ) in DMSO.
Preparation Note
Following initial use, aliquot and refrigerate (4°C).
Analysis Note
Single spot by TLC
Other Notes
Borowski, P., et al. 2003. Eur. J. Biochem.270, 1645.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun.306, 129.
Sarno, S., et al. 2003. Biochem. J.374, 639.
Sarno, S., et al. 2001. FEBS Lett.496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun.208, 418."
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Carcinogenic / Teratogenic (D)
| Quality Segment | 100 |
| form | liquid |
| manufacturer/tradename | Calbiochem® |
| storage condition | OK to freeze,desiccated (hygroscopic),protect from light |
| shipped in | wet ice |
| storage temp. | 2-8°C |
